EXACT Sciences Co. (NASDAQ:EXAS)’s share price reached a new 52-week high during trading on Wednesday . The company traded as high as $42.20 and last traded at $42.43, with a volume of 798,138 shares. The stock had previously closed at $41.30.

A number of research firms have recently commented on EXAS. Vetr upgraded EXACT Sciences from a “sell” rating to a “hold” rating and set a $36.55 price objective on the stock in a research note on Tuesday, July 25th. Canaccord Genuity reiterated a “buy” rating and issued a $45.00 price objective on shares of EXACT Sciences in a research note on Thursday. Roth Capital lifted their price objective on EXACT Sciences from $40.00 to $46.00 and gave the stock a “buy” rating in a research note on Wednesday, July 26th. Lake Street Capital lifted their price objective on EXACT Sciences from $30.00 to $41.00 and gave the stock a “hold” rating in a research note on Wednesday, July 26th. Finally, BTIG Research restated a “buy” rating and set a $45.00 price target (up from $35.00) on shares of EXACT Sciences in a research note on Monday, July 17th. Six analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $40.98.

The company’s market cap is $5.12 billion. The firm’s 50 day moving average is $39.39 and its 200-day moving average is $31.69.

EXACT Sciences (NASDAQ:EXAS) last announced its earnings results on Tuesday, July 25th. The medical research company reported ($0.27) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.10. EXACT Sciences had a negative net margin of 53.41% and a negative return on equity of 29.05%. The company had revenue of $57.65 million for the quarter, compared to analysts’ expectations of $47.73 million. Equities research analysts predict that EXACT Sciences Co. will post ($1.18) earnings per share for the current year.

In other news, CFO Jeffrey Thomas Elliott sold 5,846 shares of the firm’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $39.41, for a total transaction of $230,390.86. Following the transaction, the chief financial officer now directly owns 19,861 shares of the company’s stock, valued at $782,722.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP D Scott Coward sold 1,987 shares of the firm’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $35.21, for a total transaction of $69,962.27. Following the transaction, the senior vice president now directly owns 57,603 shares in the company, valued at $2,028,201.63. The disclosure for this sale can be found here. Insiders have sold 129,291 shares of company stock worth $5,288,181 over the last ninety days. Insiders own 4.00% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of EXACT Sciences by 8.0% during the second quarter. Vanguard Group Inc. now owns 9,459,679 shares of the medical research company’s stock worth $334,589,000 after purchasing an additional 700,051 shares during the period. BlackRock Inc. increased its holdings in shares of EXACT Sciences by 1.2% during the second quarter. BlackRock Inc. now owns 6,884,886 shares of the medical research company’s stock worth $243,518,000 after purchasing an additional 80,589 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of EXACT Sciences by 98.1% during the first quarter. JPMorgan Chase & Co. now owns 4,985,657 shares of the medical research company’s stock worth $117,761,000 after purchasing an additional 2,468,376 shares during the period. OppenheimerFunds Inc. increased its holdings in shares of EXACT Sciences by 66.8% during the first quarter. OppenheimerFunds Inc. now owns 2,502,398 shares of the medical research company’s stock worth $59,107,000 after purchasing an additional 1,002,398 shares during the period. Finally, Point72 Asset Management L.P. increased its holdings in shares of EXACT Sciences by 1,534.3% during the first quarter. Point72 Asset Management L.P. now owns 2,500,476 shares of the medical research company’s stock worth $59,061,000 after purchasing an additional 2,347,476 shares during the period. 85.22% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “EXACT Sciences Co. (EXAS) Sets New 52-Week High at $42.20” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/09/08/exact-sciences-co-exas-sets-new-52-week-high-at-42-20.html.

EXACT Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.